Furthermore, additional gene mutations (especially KIT mutations), other cytogenetic abnormalities, and several clinical features such as age and white blood cell counts at diagnosis, have been identified to be associated with a high risk of relapse and poor survival in t(8;21) AML patients (4, 6). The gene discussed is KIT; the disease is acute myeloid leukemia.